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Abstract
This study demonstrates the effects of miRNA-10b on medulloblastoma proliferation through
transcriptional induction of the anti-apoptotic protein BCL2. Using a cancer specific miRNA-
array, high expression of miRNA-10b in medulloblastoma cell lines compared to a normal cer-
ebellar control was shown, and this was confirmed with real time PCR (RT-PCR). Twomedul-
loblastoma cell lines (DAOY and UW228) were transiently transfected with control miRNA,
miRNA-10b inhibitor or miRNA-10bmimic and subjected to RT-PCR, MTT, apoptosis,
clonogenic assay and western blot analysis. Transfection of miRNA-10b inhibitor induced a
significant down-regulation of miRNA-10b expression, inhibited proliferation, and induced apo-
ptosis, while miRNA-10b mimic exerted an opposite effect. Inhibition of miRNA-10b abrogated
the colony-forming capability of medulloblastoma cells, andmarkedly down-regulated the
expression of BCL2. Down-regulation of BCL2 by antisense oligonucleotides or siRNA also
significantly down-regulated miRNA-10b, suggesting that BCL2 is a major mediator of the
effects of miRNA-10b. ABT-737 and ABT-199, potent inhibitors of BCL2, downregulated the
expression of miRNA-10b and increased apoptosis. Analysis of miRNA-10b levels in 13 pri-
mary medulloblastoma samples revealed that the 2 patients with the highest levels of miRNA-
10b hadmultiple recurrences (4.5) and died within 8 years of diagnosis, compared with the 11
patients with low levels of miRNA-10b who had amean of 1.2 recurrences and nearly 40%
long-term survival. The data presented here indicate that miRNA-10b may act as an oncomir
in medulloblastoma tumorigenesis, and reveal a previously unreported mechanismwith Bcl-2
as a mediator of the effects of miRNA-10b uponmedulloblastoma cell survival.
Introduction
Medulloblastoma is the most common malignant brain tumor in children, affecting 2 per
100,000 children in the United States and worldwide, and comprising approximately 30% of
new pediatric brain tumor diagnoses. Patients with clinical standard-risk disease have 5-year
survival rates that approach 80%, while those with high-risk disease have much lower survival
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rates. The side effects of the treatment course, which involves surgery, craniospinal radiation
therapy and intensive chemotherapy, are considerable. Attempts to predict outcome based
upon pathologic subtype, genetic mutations, and protein expression have been largely unsuc-
cessful. The development of new therapeutic targets is essential to increasing survival rates and
reducing therapy-related side effects.
Medulloblastoma represents a heterogeneous group of tumors that has recently been cate-
gorized into 4 subgroups on the basis of clinical factors and molecular signature [1]. The WNT
subgroup has a very good prognosis, and may benefit from treatment modification to minimize
morbidity. No cell line has been developed that represents this subgroup well. Up to 50% of
tumors in the SHH subgroup are pathologically classified as desmoplastic or nodular medullo-
blastomas. While the DAOY cell line was derived from a desmoplastic medulloblastoma, the
cytogenetics are atypical for the SHH subgroup. Group 3 tumors carry a very poor prognosis,
and metastases are often present at the time of diagnosis. There is a need to accurately identify
these tumors soon after surgical resection, and to develop treatments tailored to biomarkers
specific to this tumor subgroup. Cell lines such as D341, probably D283 (which also has an iso-
chromosome 17), UW402, UW228 [2], and D425 are MYC-amplified and most closely resem-
ble group 3 tumors [3]. Group 4 tumors most frequently have an isochromosome 17q, are
often metastatic at the time of diagnosis, and have an intermediate prognosis. This is the most
common, and the least understood, tumor subgroup [1].
MicroRNAs (miRNAs) are small, highly conserved RNAmolecules that regulate gene expres-
sion post-transcriptionally, by inhibiting the translation of target mRNAs into protein or by
degrading target mRNAs [4]. Aberrant expression of miRNAs has been shown to play an impor-
tant role in the pathogenesis and metastasis of various malignancies [5–7]. Oncogenic miRNAs
have been shown to promote carcinogenesis by targeting tumor suppressors such as cell cycle
regulators and pro-apoptotic genes [8,9]. Such oncomirs are potential therapeutic targets.
Recent miRNA expression profiling studies revealed a number of miRNAs implicated in
medulloblastoma initiation and progression through effects on genes and proteins responsible
for cell proliferation or cell death [10,11]. Overexpression of miRNA-10b associated with
tumorigenesis has been reported in a number of tumor types, including low-grade glioma [12–
16], breast cancer [14], and esophageal cancer [17]. Increased expression of miRNA-10b has
been shown to promote proliferation by inactivating the expression of pro-apoptotic genes
[12,13,17,18,19]. Gabriely et al have shown that human glioma growth is controlled by
miRNA-10b directly targeting BCL2L11 / Bim, a proapoptotic protein commonly activated in
response to chemotherapy [16]. These studies strongly suggest that miRNA-10b is an oncomir,
and plays an important role in oncogenesis by controlling multiple cellular pathways.
This study demonstrates the effect of miRNA-10b on medulloblastoma growth and prolifera-
tion through transcriptional induction of BCL2, a cellular proto-oncogene and tumor promoter.
A loss of function approach was used to elucidate miRNA-10b function in medulloblastoma. In
this study, the effects of ABT-737 and ABT-199, potent specific inhibitors of BCL2, on miRNA-
10b expression were examined. High levels of miRNA-10b were found to correlate with multiple
tumor recurrences and low survival in patient samples. Collectively, our data demonstrate that
BCL2 is an important mediator of the effects of miRNA-10b in medulloblastoma, and suggest a
potential new therapeutic approach in the treatment of medulloblastoma.
Material and Methods
Cell lines and reagents
DAOY, D341 and D283 human MB cell lines were purchased from American Type Culture
Collection (Manassas, VA). UW228, UW402 and UW426 were the gifts of Dr John R. Silber
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(University of Washington, WA).[2] D384 Med and D425 Med cell lines were the gifts of Dr
Darell D. Bigner (Duke University, Durham, NC).[3] All cell lines were passaged for no more
than 6 months after receipt or resuscitation, and so authentication from the sources was
accepted. No de novo cell lines were used or generated for this project. MB cell lines except
D341 were cultured in DMEMmedium supplement with 1X penicillin/streptomycin and 10%
fetal bovine serum (FBS) at 37°C and 5% CO2. The D341 cell line was cultured in DMEM with
20% FBS with 1% penicillin/ streptomycin at 37°C and 5% CO2. Antibodies against BCL2 were
purchased from Cell Signaling Technology, Inc, and against β- actin from Sigma-Aldrich.
ABT-199 and ABT-737 were purchased from Active Biochem and dissolved in DMSO for
stock solution. DAOY and UW228 cells were treated with DMSO (control group) or with vary-
ing concentrations of ABT-737 and ABT-199 in DMEM supplemented with 1X penicillin/
streptomycin and 10% fetal bovine serum (FBS) at 37°C and 5% CO2 for 2 days. Cells were sub-
jected to RNA extraction, MTT and apoptosis assays.
Patient samples
Patient medulloblastoma samples were collected from the University of Pittsburgh Brain Tumor
Bank after University of Pittsburgh Institutional Review Board approval was obtained. Informed
consent was not obtained as the samples were analyzed restrospectively after being stored in the
Brain Tumor Bank. Thirteen medulloblastoma specimens were analyzed for this study. All sam-
ples were stored in liquid nitrogen immediately after resection and stored at -80°C until use. The
ages of the patients included in this study ranged from eight month to 26 years. The majority of
patients were male (70%), and 70% of these patients died of their disease (Table 1). Normal cere-
bellar samples from autopsied patients were obtained from the neuropathology Reference RNA
(Ambion) to ensure that there was no difference in miRNA production between normal human
cerebellum and the pooled brain tissue frommultiple brain regions used for the First Choice
Human Brain Reference RNA. No difference was found (data not shown).
RT-PCR analysis for miRNA expression
Total RNA was extracted from the cell lines, normal cerebellar control samples, and patient
medulloblastoma samples using the Qiagen miRNAeasy Mini Kit and the manufacturer’s
Table 1. miRNA-10b expression correlates with survival and recurrence in humanmedulloblastoma patient samples. Human biopsy samples were
subjected to RNA extraction followed by generation of cDNA, and subjected to RT-PCR for analysis of miRNA-10b expression. The fold expression of
miRNA-10b was compared to the normal cerebellar control. miRNA-10b expression was correlated with the patients’ clinical and pathological history.
Patient
#
Gender Age at
surgery
Time to
recurrence
#Recurrences Time to
Death
MIB-1 Pathologic
subtype
Molecular
subgroup
miRNA-10b
expression
1 F 3y10m 16m 4 3y11m 35% Classic Group 3 1.947
2 M 34m 13m 1 2y1m 45% Desmoplastic SHH 0.0816
3 M 25 53m 1 5y4m 80% Desmoplastic SHH 1.043
4 M 12 31m 1 4y9m 43.60% Classic Group 4 0.414
5 F 16 27m 4 7y5m 57.10% Classic Wnt 198.400
6 M 7y9m none 0 60% Desmoplastic Group 4 2.472
7 F 2y11m none 0 65.40% Desmoplastic Wnt 13.056
8 M 13m none 0 40–
50%
Desmoplastic SHH 0.233
9 M 4y5m 16m 1 1y8m 33.30% Classic Group 3 7.223
10 M 8m 14m 3 3y2m 36.10% Desmoplastic SHH 0.260
11 M 16 none 0 34.32% Classic Group 4? 52.740
13 F 26 6m 5 4y8m 30% Classic 589.254
14 M 17m 4m 2 8m 40% Classic 0.448
doi:10.1371/journal.pone.0137845.t001
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protocol. Total RNA was converted into miRNA first strand cDNA using the RT2 miRNA First
Strand kit for the DAOY and D341 cell lines, human medulloblastoma samples, and the
human cerebellar control samples. Quantitative reverse transcription polymerase chain reac-
tion (RT-PCR) was performed on a Bio-Rad iCycler using 25 ul of cDNA and RT2 SYBR Green
qPCR master mix per well in a 96-well miRNA Human Cancer array. A three-step cycling pro-
gram (10 minutes at 95°C, 40 cycles of 15 seconds at 95°C, 30 seconds at 60° and 30 seconds at
72°C) was used. The resulting threshold cycle values for all wells were exported to an Excel
spreadsheet for use with the miRNA PCR Array Data Analysis Template. Expression analysis
of the 88 cancer-specific miRNA sequences selected for the Human Cancer RT2 miRNA PCR
array was performed. All materials were purchased from SA Biosciences unless otherwise
indicated.
For the determination of miRNA levels of miRNA-10b, miRNA-17 and miRNA-20b, the
average threshold cycle (CT) for expression of each miRNA was determined from triplicate
reactions, and data were analyzed using the difference between threshold PCR cycles values for
target and control genes (ΔCT). miRNA expression was normalized to internal control RNA
such as SNORD 47 and SNORD 48 using the ΔCT values. Each result was calibrated to the cere-
bellar control to give the ΔΔCT value, in which the control had a ΔΔCT value of 0. The fold tar-
get miRNA expression compared with the calibrated value is given by the formula: 2- ΔΔCT.
Transfection studies
DAOY and UW228 cell lines were transfected with control miRNA, miRNA-10b inhibitor
(miRNA-10b-AS) (GeneCopoeia, Rockville, MD), or miRNA-10b oligonucleotide (Qiagen)
using the Lipofectamine RNAiMAX reagent (Invitrogen) for the control miRNA and anti-
miRNA-10b as per the manufacturer’s guidelines. For the miRNA-10b mimic studies, the
transfection was performed with the control miRNA or miRNA-10b oligonucleotide using the
LTI reagent (Mirus, Madison, WI). All transfections were carried out in 24-well plates using
2 x 104 cells / well in 500μl of medium. Protein and RNA from the transfected cells were
extracted for analysis of miRNA-10b, BCL2 and Mcl-1 expression. For the experiments assess-
ing the effect of silencing of BCL2, DAOY cells (2 x 104 cells /well) were plated in 24-well plates
24 hours before transfection. Plated cells were transfected with Dicer substrate 27-mer duplexes
targeting BCL2 mRNA and scrambled universal negative control RNA duplex (Origene, Rock-
ville, MD). On the day of transfection, 500 μl of fresh medium and 10nM of siRNA were mixed
with the transfection reagent (Lipofectamine RNAiMAX reagent) as per the manufacturer’s
instructions and added to each well. The cells were harvested for RNA and protein extraction
after 48 hrs for RT-PCR and Western blot analysis.
Western blot analysis
Briefly, the cells were lysed with 1X radioimmunoprecipitation assay buffer (Santa Cruz Bio-
technology Inc) with a cocktail of protease inhibitors, sodium benzoate and phenylmethylsul-
fonyl fluoride. Cell lysates were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, and transferred to polyvinyl difluoride membranes (Bio-Rad Laboratories).
The blots were incubated with the respective antibodies for protein expression and the immune
complexes were detected using enhanced chemiluminescence (Amersham).
Cell proliferation assays
Cell proliferation was measured by MTT assay (Cayman Chemical Company, MI). Briefly,
medulloblastoma cells were plated in six-well plates and transfected with control miRNA, anti-
miRNA-10b-, or miRNA-10b mimic. After 48 hours, 5000 transfected cells / well were seeded
miRNA-10b Is Overexpressed in Medulloblastoma
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in 96-well plates in 100 μl of medium. Ten μl of MTT reagent were added to each well, and the
cells were incubated for 3 hrs at 37°C. Absorbance was measured at 570 nm using a microplate
reader according to the manufacturer’s recommendations. Relative cell number was calculated
by normalizing the absorbance to that of untreated cells.
Apoptosis assay
Apoptosis was analyzed using a cell death detection ELISA kit (Roche Diagnostics, Indianapo-
lis, IN) based on a photometric enzymatic immunoassay for the quantitative in vitro determi-
nation of cytoplasmic histone-associated DNA fragments as described 11. Briefly, equal
numbers of medulloblastoma cells were seeded in six-well plates and transfected with the con-
trol miRNA, miRNA-10b-AS or miRNA-10b mimic. The cytoplasmic fraction was collected
from each sample after 48 hours of transfection as per the manufacturer’s protocol. The cyto-
plasmic fractions were incubated with biotin- labeled monoclonal anti-histone antibody, fol-
lowed by incubation with peroxidase-conjugated monoclonal anti-DNA antibody. Color
development was assessed with ABTS substrate measured at 405 nm against substrate solution
as a blank control.
Clonogenic assay
To determine the ability of medulloblastoma cells to clonally expand and create colonies, cells
were transfected with control miRNA, miRNA-10b-AS or miRNA-10b mimic for 48 hours,
and seeded in 6-well plates (3000 cells/ well) in triplicate. After 7 days of incubation at 37°C,
the plates were gently washed with PBS. The colonies were stained with Hema3 Manual Stain-
ing Systems (Fisher Scientific). The plates were scanned, and images were represented in JPG
format and placed into figures using Adobe Photoshop Version 7.0 Professional (Adobe
Systems).
Statistical analyses
Each experiment was repeated in at least triplicate, and all quantitative data are presented as
mean plus or minus SD. Statistical differences were determined by Student’s t test. The results
were considered statistically significant with p values< .05.
Results
miRNA-10b is highly expressed in medulloblastoma cells
To investigate the profiling of oncomirs in medulloblastoma pathobiology, a cancer-specific
miRNA-array was performed. From the oncomir microarray, miRNA-10b was identified as one
of the most highly and significantly upregulated miRNAs in medulloblastoma cell lines when
compared to a normal cerebellar control (Fig 1A left panel). We decided to investigate miRNA-
10b expression further because miRNA-10b has been reported to be strongly associated with can-
cer 13,18,19, to play a role in cellular proliferation and survival16, and because its role in medullo-
blastoma is still unknown. miRNA-10b is not expressed in normal brain. While HRK was also
significantly upregulated, its pro-apoptotic role made it a less attractive subject for further study
of proliferation. To confirm the high expression of miRNA-10b, we analyzed its expression by
quantitative RT-PCR in eight medulloblastoma cell lines. We found that miRNA-10b expression
was significantly upregulated (42–100 fold) in five medulloblastoma cell lines (DAOY, UW228,
UW402, UW426, and D341Med) (Fig 1B) compared to the control. Three medulloblastoma cell
lines (D283, 384 Med, and 425 Med) from this study showed no expression of miRNA-10b. The
DAOY (SHH subgroup) and UW228 (Group 3) medulloblastoma cell lines showed the highest
miRNA-10b Is Overexpressed in Medulloblastoma
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miRNA-10b expression, and so these cell lines were utilized for further functional studies target-
ing miRNA-10b.
miRNA-10b induces medulloblastoma proliferation
To investigate the effects of miRNA-10b inhibition on medulloblastoma cells, DAOY and
UW288 cells were transfected with control miRNA, anti-miRNA10b or miRNA-10b mimic.
RT-PCR analysis showed that transfection of anti-miRNA10b significantly (P 0.001) inhib-
ited the endogenous expression of miRNA-10b in both cell lines as compared to the control
miRNA (Fig 2A). Transfection of miRNA10b significantly (P 0.001) upregulated miRNA10b
expression in DAOY (12.55-fold compared to the control) and UW 228 (18.32-fold compared
to the control) cells (Fig 2A), evidence that the transfection system is functioning well. Thus,
manipulating the expression of miRNA-10b can be utilized to elucidate the functional effects
of miRNA-10b on medulloblastoma cellular growth and survival.
The effects of miRNA-10b on proliferation and apoptosis induction in medulloblastoma
were explored.). As miRNA-10b promotes cellular proliferation, transfection with miR-10b
mimic was expected to promote proliferation and have little effect on apoptosis, while transfec-
tion with anti-miR-10b was expected to produce apoptosis and inhibit prolferation. These
hypotheses were confirmed with the following investigations. Transfection of DAOY and
UW228 MB cell lines with anti-miRNA-10b resulted in significant (P 0.001) inhibition of
proliferation compared with cells transfected with control miRNA (Fig 2B). This was measured
by MTT proliferation assay by quantifying the intracellular NAD(P)H-oxidoreductase. Trans-
fection with miRNA-10b mimic significantly induced proliferation in both medulloblastoma
cell lines (Fig 2B). The role of inhibition of miRNA-10b in the induction of medulloblastoma
apoptosis was assessed. Medulloblastoma cells were transfected with control-miRNA, anti-
Fig 1. miRNA-10b is highly expressed in medulloblastoma cells. Total RNA was extracted frommedulloblastoma cells and subjected to RT-PCR
analysis. (A) Oncomir microarray using quantitative RT-PCR in DAOY cells compared to normal cerebellum and FirstChoice1 Human Brain Reference RNA.
MicroRNA heat map profile. (B) Increased expression of miRNA-10b in the majority of medulloblastoma cell lines (DAOY, UW228, UW402, UW426 and
D341 Med).
doi:10.1371/journal.pone.0137845.g001
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miRNA10b or miRNA-10b mimic, and were analyzed by cell death detection ELISA. Signifi-
cant induction of apoptosis by anti-miRNA-10b (P 0.001) (158.07% ± 5.38) andslightly
decreased apoptosis in the presence of miRNA-10b mimic (97.20% ± 9.33) compared to con-
trol miRNA (100% ± 2.87) were observed in DAOY cells (n = 4 experiments; Fig 2C). A more
significant (P 0.001) pattern was observed in the UW228 cell line, with anti-miRNA10b
(335.94% ± 17.68) and miRNA10b mimic (93.47% ± 5.70) compared to control miRNA (100%
± 6.53) (Fig 2C) The effect of the inhibition of miRNA10b on tumor cell growth was examined.
DAOY and UW228 cells were transfected with control miRNA, anti-miRNA10b or miRNA-
10b mimic for 48 hours. The transfected cells were plated for clonogenic growth. As shown in
Fig 2D, miRNA-10b inhibition significantly inhibited clonogenic cell growth in both medullo-
blastoma cell lines. In the DAOY cell line, miRNA10b inhibition reduced colony formation by
almost 70% as compared to control miRNA (58.66 ± 4.71 / 170 ± 5). In contrast, miRNA-10b
mimic induced a20% increase in clonogenic growth compared to control (204.33± 6.02 /
170 ± 5) (Fig 2D). The same pattern was observed for the UW228 cell line for clonogenic
growth (data not shown). Our data suggests that inhibition of miRNA-10b in medulloblastoma
decreases proliferation via the induction of apoptosis, resulting in significant abrogation of
clonogenic growth. In contrast, overexpression of miRNA-10b enhances proliferation and clo-
nogenic growth by preventing apoptosis, implicating miRNA-10b in medulloblastoma prolifer-
ation and survival.
Fig 2. Inhibition of miRNA-10b inhibits cell proliferation and induces apoptosis. (A) Medulloblastoma
cells were transfected with control miRNA, anti-miRNA-10b or miRNA-10b mimic. Total RNA was extracted
after 48 hours of transfection and subjected to RT-PCR analysis for miRNA-10b expression. Error bars
represent SD of the mean from at least 4 determinations. (B) Proliferation of transfected medulloblastoma
cells with control miRNA, anti-miRNA-10b or miRNA-10b was analyzed by MTT proliferation assay
measuring the intracellular NAD(P)H-oxidoreductase. (C) Percentage of apoptotic transfected cells was
analyzed using a photometric cell death detection ELISA for identification of cytoplasmic histone-associated
DNA fragments (n = 4). All results are represented as mean ± SD. (D) For the clonogenic growth assay,
DAOY cells were transfected with miRNA-10b or inhibitor. After 24 hours, cells were seeded in 6-well plates
(3000 cells/ well in triplicate). The plates were stained with the Hema 3 manual system after 12 to 14 days of
incubation at 37°C. Left: representative photographs of the colonies; right: graphical representation of the
colonies with over 50 cells ((** P 0.05 and *** P 0.001 according to student’s t-test).
doi:10.1371/journal.pone.0137845.g002
miRNA-10b Is Overexpressed in Medulloblastoma
PLOSONE | DOI:10.1371/journal.pone.0137845 September 22, 2015 7 / 15
Relationship between miRNA-10b and Bcl-2 expression
We hypothesize that induction of apoptosis may be a major pathway by which miRNA-10b
inhibition decreases the proliferation and survival of medulloblastoma cells. To investigate the
modulation of apoptotic proteins by miRNA-10b, we performed a human apoptosis PCR array
under the influence of miRNA-10b inhibitor transfection. Interestingly, we found in the gene
array (Fig 3A) studies that inhibition of miRNA-10b significantly downregulated Bcl2 (-5.13
fold change) and anti-apoptotic Bcl2 family members such as BCL2A1 and BCL2L1. Tran-
scriptional induction of Bcl2 is a major mechanism for apoptosis evasion in cancer cells. We
found that inhibition of miRNA-10b resulted in significant inhibition of endogenous BCL2
and (anti-apoptotic) MCL-1 protein expression, and that overexpression of miRNA-10b
increased expression of BCL2 and MCL-1 by western blot analysis (Fig 3B), suggesting that
Bcl2 is under the control of miRNA-10b. There was no effect observed on the expression of
pro-apoptotic BCL2 family members Bax, Bim and Bid (S1 Fig), which suggests that miRNA-
10b is specifically targeting the expression of Bcl2 for the induction of proliferation in medullo-
blastoma. The 94-fold reduction in HRK expression is notable. This pro-apoptotic protein was
not deemed a likely candidate for promoting proliferation in medulloblastoma, but this finding
will be pursued in further studies. These data suggest that high levels of BCL2 may play a role
in increasing the survival of medulloblastoma cells, and that miRNA-10b inhibits apoptosis
and induces proliferation by targeting BCL2, an anti-apoptotic protein.
Silencing of BCL2 also downregulates miRNA-10b expression
It has been previously reported that downregulation of BCL2 by antisense oligonucleotides or
siRNAs leads to apoptosis, and sensitizes cancer cells to chemotherapy and radiation therapy
[20–24]. It was hypothesized that downregulation of BCL2 would downregulate miRNA-10b,
and thus induce apoptosis and growth inhibition in medulloblastoma cells. BCL2 expression
was assessed in the same group of 8 medulloblastoma cell lines which had been previously
assessed for the expression of miRNA-10b (Fig 1B) and it was found that the cell lines with
high levels of miRNA-10b expression also had high levels of Bcl2 expression. DAOY and
UW228, the two cell lines which were used for all of the experiments in this study, showed very
high expression of both miRNA -10b and BCL2 (Fig 4A). DAOY cells were used in this
Fig 3. Anti-apoptotic BCL2 family members are downregulated by inhibition of miRNA-10b. (A) A
human apoptosis array was used for the identification of apoptotic genes influenced by the inhibition of
miRNA-10b. Total RNA was extracted from DAOY cells transfected with anti-miRNA-10b, and then subjected
to RT-PCR for the analyses of apoptotic genes. The pale grey in the figure at right references the genes
identified in the table at left. (B) Medulloblastoma cells were transfected with control miRNA, anti-miRNA-10b
or miRNA-10b mimic. Lysates of transfected cells were subjected to Western blotting using (A) anti-BCL2
antibody (B) anti-MCL1 antibody. β-actin was used as a loading control.
doi:10.1371/journal.pone.0137845.g003
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experiment. Treatment of DAOY cells with two different BCL2 siRNAs (10 nM) resulted in
reduction of BCL2 protein expression of 75to 85% relative to control cells, as shown by West-
ern blot performed at 48h of treatment (Fig 4B). The downregulation of BCL2 by BCL2 siRNA
was demonstrated to inhibit the endogenous expression of miRNA-10b as detected by RT-PCR
(Fig 4C). These findings suggest that apoptotic induction after miRNA-10b blockade is depen-
dent to a significant degree on BCL2 downregulation.
Down-regulation of miRNA-10b by potent BCL2 inhibitors
Our preliminary studies indicated that miRNA-10b is an oncomir regulating the growth and
survival of medulloblastoma cells by controlling the levels of BCL2. It was hypothesized that
potent inhibitors of BCL2, known for their antiproliferative and apoptotic effects on medullo-
blastoma cells, inhibit the expression of miRNA-10b [25]. DAOY and UW228 cells were cul-
tured with ABT-737 and ABT-199 as described in “Cell lines and reagents.” DMSO was used
as a control. ABT-737, a BCL2 antagonist, has been shown to inhibit proliferation and induce
apoptosis in medulloblastoma cells at 10 μM [25]. Concentrations ranging from 0.5 μM
-10 μM for ABT-737 and ABT-199 were tested. Both ABT-737 and ABT-199 significantly (P
0.001) inhibited endogenous miRNA-10b expression (Fig 5A and 5B) in a dose-dependent
manner. ABT-737 and ABT-199 also significantly inhibited the proliferation of medulloblas-
toma cells as measured by MTT assay (Fig 5C), and induced apoptosis (Fig 5D), both in a
dose-dependent manner.
The specificity of the inhibition of miRNA-10b expression by the BCL2 inhibitors was
investigated. The BCL2 inhibitors ABT-737 and ABT-199 had no inhibitory effects on
miRNA-17 and miRNA-20b expression (S2 Fig); these miRNAs were investigated because they
were significantly upregulated in the cancer miRNA array (Fig 1A). These results suggest that
miRNA-10b is specifically inhibited by the BCL2 inhibitors. To our knowledge this is the first
study reporting the effects of ABT-199 on the growth and survival of medulloblastoma cells.
Fig 4. Knockdown of BCL2 by specific siRNA induces significant inhibition of miRNA-10b expression.
DAOY, UW228, D283 384 Med, 425 Med, UW426 and UW402 medulloblastoma cells were collected and
lysed, and cell lysates were fractionated by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred onto PVDFmembranes to determine BCL2 protein expression byWestern blot
analysis. The membrane was stripped and reprobed with an anti-β-actin antibody to confirm equal loading of
protein in each lane. (B) DAOY cells were transfected with two different siRNAs (# 1 and #2) (10nM) specific
for the BCL2 transcript, or with scrambled universal negative control RNA duplex (DS Scrambled Neg)
(10nM). After 48 hours, cells were collected and BCL2 and β-actin expression was determined. (C) After 48
hours of BCL2 and negative control siRNA (10nM) treatment, total RNA was extracted, and mRNA levels of
miRNA-10b were determined by RT-PCR analysis as described in Materials and Methods. Experiments were
repeated at least three times. (** P 0.05 and *** P 0.001 according to student’s t-test)
doi:10.1371/journal.pone.0137845.g004
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This study suggests that BCL2 is an important mediator of miRNA-10b activity in medullo-
blastoma, and suggests a new therapeutic target.
miRNA-10b expression correlates with survival and recurrence in
patients with medulloblastomas
The correlation between the expression of miRNA-10b in vivo and the disease course in patients
with medulloblastoma was investigated. miRNA-10b levels were measured in 13 primary medul-
loblastoma samples, and compared to a normal cerebellar control. As shown in Table 1, elevated
levels of miRNA-10b expression (13–550 fold) compared to the control (P 0.001) were detected
in 4 primary medulloblastoma samples. The 2 patients with the highest levels of miRNA-10b
expression (more than a 200-fold increase versus control) had multiple recurrences (an average
of 4.5) and died within 8 years of diagnosis, compared with the 11 patients with lower levels
of miRNA-10b expression who had a mean of 1.2 recurrences and 36% long-term survival
(Table 1). The molecular subtype classification of the tumor samples was graciously provided by
the laboratory of Michael D Taylor (Hospital for Sick Children, Toronto, Canada). The age, gen-
der, MIB-1 proliferation index, pathologic subtype andmolecular subgroups of the patients were
not correlated with the levels of miRNA-10b expression. One patient with high expression of
miRNA-10b had a tumor classified as being in theWnt subgroup. Our laboratory studies were
performed on the Daoy (SHH subgroup) and UW228 (group 3) cell lines, the lines with the high-
est levels of miRNA-10b expression. These facts are evidence that the role of miRNA-10b is more
generalized and basic in the disease process, rather than having an effect in only a certain sub-
group of tumors. Patients with high levels of miRNA-10b expression had poor survival and
multiple tumor recurrences when compared to the patients with lower levels of miRNA-10b
Fig 5. Down-regulation of miRNA-10b by BCL2 inhibitors is associated with the inhibition of
proliferation by induction of apoptosis.Medulloblastoma cells were incubated with BCL2 inhibitors ABT-
737 and ABT-199 for 48 hours. DMSO 0.1% was used as a control treatment. Total RNA was extracted from
DAOY and UW228 cells, and subjected to RT-PCR for the analysis of miRNA-10b expression under the
influence of BCL2 inhibitors (A) ABT-737 and (B) ABT-199. (C) ABT-737 and ABT-199 significantly inhibit the
proliferation of medulloblastoma cells measured by MTT assay (D) ABT-737 and ABT-199 significantly
induce the apoptosis of medulloblastoma cells measured by cell death detection ELISA. (** P 0.05 and
*** P 0.001 according to student’s t-test)
doi:10.1371/journal.pone.0137845.g005
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expression, correlating with our laboratory studies that indicate that miRNA-10b plays a role in
medulloblastoma proliferation and inhibits apoptosis. Targeting of miRNA-10b with therapeutic
intervention may lead to success in a large subset of patients, as miRNA-10b expression is not
restricted to any known disease classification for medulloblastoma.
Discussion
Medulloblastoma is the most common malignant brain tumor in children, and is associated
with significant morbidity and mortality [26]. Current treatment methods are not tailored to
the individual tumor, and convey significant long-term morbidity to the surviving patient
[27,28]. Approximately one-third of patients remain refractory to therapy [29]. Resistance to
therapy and relapse are hypothesized to be due to the deregulation of apoptotic factors such as
the BCL2 family members [30]. These proteins are key regulators of apoptosis in the cerebellar
granule cell precursors from which medulloblastoma are thought to arise [31,32]. miRNAs
have been shown to target oncogenes to regulate cellular proliferation and survival [5,33,34],
and have been implicated in the pathogenesis of medulloblastoma [35]. miRNA-10b has been
shown to play an important role in the regulation of cell survival and proliferation [16], and to
function as an oncomir in various types of malignancies [13,14,19]. This study demonstrates
that miRNA -10b regulates the proliferation and survival of medulloblastoma cells by targeting
BCL2. From an oncomir microarray, we demonstrated that miRNA-10b is one of the most
highly upregulated miRNAs in medulloblastoma cell lines compared to the normal cerebellum.
We observed that overexpression of miRNA-10b induces cellular proliferation and protects
against apoptosis in medulloblastoma cell lines. Inhibition of miRNA-10b significantly induced
apoptosis, resulting in the inhibition of proliferation of medulloblastoma cells. The Wnt and
Sonic hedgehog pathways are known to have downstream effects on BCL2 transcription
[36,37,38]. These regulatory effects may be mediated in some cases by miRNA-10b. These data
suggest that therapies targeting miRNA-10b may be effective in the treatment of some or all of
the molecular subgroups of medulloblastoma patients.
Our data indicates that the apoptosis induced by miRNA-10b blockade seems to be caused
at least in part by changes in the expression of the anti-apoptotic protein BCL2. We found that
endogenous levels of BCL2 are very well-correlated with miRNA-10b expression. DAOY and
UW228, the cell lines with the highest levels of miRNA-10b expression, also showed the high-
est levels of BLC2 expression. In contrast, 384 Med and 425 Med, the cell lines with no expres-
sion of miRNA-10b, also showed no BCL2 expression. We found that overexpression of
miRNA-10b significantly induced the expression of BCL2 in both the DAOY and UW228 cell
lines, suggesting that miRNA-10b positively regulates BCL2 in medulloblastoma cells. In con-
trast, inhibition of miRNA-10b by anti-miRNA10b resulted in decreased BCL2 expression, and
was accompanied by increased sensitivity of medulloblastoma cells to apoptosis. Our data pro-
vide strong evidence that miRNA-10b regulates BCL2 expression, and thus induces the prolif-
eration of medulloblastoma cells. This mechanism could be responsible for resistance to
chemotherapeutic drugs in some cases [39].
To further define the role BCL2 plays in apoptosis induced by miRNA-10b inhibition, we
inhibited BCL2 expression in medulloblastoma cells, which resulted in significant downregula-
tion of miRNA-10b expression. This indicates that miRNA-10b is regulated by BCL2, and
miRNA-10b blockade seems to be caused at least in part by changes in the expression of the
anti-apoptotic protein BCL2. This is further supported by the fact that two medulloblastoma
cell lines with no endogenous expression of miRNA-10b also have no BCL2 expression, sug-
gesting that high levels of miRNA-10b increase BCL2 levels, thereby increasing the prolifera-
tion and survival of medulloblastoma cells.
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Our data showed that by regulating the anti-apoptotic protein BCL2, miRNA-10b produces
oncogenic effects. Because BCL-2 inhibition downregulated miRNA-10b expression, we inves-
tigated whether BCL2 inhibitors could be used to inhibit the effects of miRNA-10b. ABT-737 is
a BCL2 homology 3 (BH3)-mimetic that induces apoptosis by inhibiting pro-survival BCL2
proteins [40]. High levels of BCL2 were shown to correlate with ABT-737 sensitivity in CLL
[41,42]. ABT-737 is under early-phase clinical evaluation as single agent therapy for CLL at
present, but preclinical studies highlight its potential for use in combined modality therapies
[43]. The main obstacle to its implementation appears to be a side effect of thrombocytopenia.
Levesley et al showed that ABT-737 induces apoptosis in medulloblastoma cells [25]. We
found that ABT-737 inhibits miRNA-10b expression in a dose-dependent fashion, and that
this is accompanied by the inhibition of cell proliferation and increased induction of apoptosis.
Recently Souers et al[44] showed that ABT-199 is a first-in-class orally bioavailable BCL2 selec-
tive inhibitor that shows potent cell killing in vitro and high antitumor efficacy in vivo. In our
study, ABT-199 inhibited medulloblastoma cellular proliferation by induction of apoptosis in a
dose- dependent fashion, and also inhibited miRNA-10b expression.
To our knowledge, we are the first to report that miRNA-10b is involved in the regulation of
proliferation and survival in medulloblastoma. Our findings on the role of miRNA-10b in
medulloblastoma are in agreement with previous reports describing its role in the proliferation
and maintenance of glioma cells by regulating various apoptotic proteins [16]. Gabriely et al
suggested that miRNA-10b has effects upstream of the cell cycle and antiapoptotic genes, con-
trolling major pathway divergence points between proliferation and cell death in glioma [16].
Of note, miR-34a expression was downregulated on our initial oncomir microarray (Fig 1),
inversely correlated with miR-10b as it has been reported to be with Bcl-2 expression in glio-
mas. [45] The effect of miR-10b on Bcl-2 may occur through a loss of miR-34a in medulloblas-
toma. We are the first group to report upon the inhibition of miRNA expression by the BCL2
inhibitors ABT-737 and ABT-199. The ongoing clinical evaluation of BCL-2 inhibitors and
this new knowledge of the effects of these drugs on miRNA-10b expression may broaden their
application as a new chemotherapeutic class, an anti-miRNA drug.
Kaplan-Meier survival analysis available through the TCGA Cancer Molecular Analysis
Portal [46] suggested that miRNA-10b expression may correlate with patient survival [47].
Our patient data showed that patients with high miRNA-10b levels have much shorter survival
and more tumor recurrences compared with patients with low miRNA-10b expression. The
fact that the patient data correlated with miRNA-10b expression but not with their molecular
subgroup classification argues that the use of miRNA-10b as a biomarker is more broadly
applicable than to simply identify a single molecular subgroup. Our data strongly support the
oncogenic role of miRNA-10b in medulloblastoma cellular proliferation.
In summary, we describe the functional role of miRNA-10b in medulloblastoma. We dem-
onstrate that high levels of miRNA-10b increase medulloblastoma proliferation by directly or
indirectly regulating BCL2 levels, thereby controlling apoptosis. The mechanistic steps between
miRNA-10b and BCL2 in medulloblastoma have yet to be elucidated. Our data suggest that
regulation of BCL2 by miRNA-10b is associated with proliferation and survival of medulloblas-
toma cells.
Supporting Information
S1 Fig. Pro-apoptotic BCL-2 family members are not affected by miRNA-10b expression.
Medulloblastoma cells were transfected with control miRNA, anti-miRNA-10b, or miRNA-
10b mimic. Lysates of transfected cells were subjected to Western blotting using anti-Bim, anti-
Bcl-xl, anti-Bid, and anti-Bax antibodies. β-actin was used as a loading control. Thus, the effect
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of miRNA-10b expression on BCL-2 is specific to certain BCL-2 family members.
(TIFF)
S2 Fig. The effect of BCL2 inhibition is specific to miRNA-10b.Medulloblastoma cells
(DAOY) were incubated with the BCL2 inhibitors ABT-737 and ABT-199 for 48 hours.
DMSO 0.1% was used as control treatment. Total RNA was extracted from DAOY cells and
subjected to RT-PCR for the analysis of (A) miRNA-17 and (B) miRNA-20b expression under
the influence of BCL2 inhibitors ABT-737 and ABT-199. Error bars represent SD from the
mean from at least 4 repeat experiments. This demonstrates that the effect of BCL2 inhibition
on miRNA-10b is specific to miRNA-10b.
(TIFF)
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